Kyntra Bio (KYNB) vs MetaVia (MTVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MetaVia is the larger company by market cap ($6.8 million vs $6.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYNB | MTVA |
|---|---|---|
| Share price | $1.56 | $1.01 |
| Market cap | $6.32M | $6.81M |
| 1-day change | -13.33% | -7.34% |
| YTD return | -82.23% | — |
| 1-year return | -81.47% | — |
| 5-year return | -99.49% | — |
| EPS (TTM) | $-4.35 | $-2.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.44M | — |
| Revenue growth (YoY) | -78.26% | — |
| Net income (latest FY) | $183.45M | $-12.97M |
| Gross margin | 91.37% | — |
| Operating margin | -712.66% | — |
| Net margin | 2848.63% | — |
| 52-week high | $10.47 | $13.42 |
| 52-week low | $1.56 | $0.966 |
| Distance from 52-week high | -85.10% | -92.47% |
| Analyst consensus | none | none |
| Avg. price target upside | +2442.95% | +1813.86% |
| Average volume | 29.96K | 113.44K |
| Shares outstanding | 4.05M | 6.74M |
| Employees | 34 | 8 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kyntra Bio
KYNB stock →Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About MetaVia
MTVA stock →MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
KYNB vs MTVA FAQ
Which is bigger, Kyntra Bio or MetaVia?
MetaVia (MTVA) is larger, with a market capitalization of $6.81M compared with $6.32M for Kyntra Bio (KYNB).
Are Kyntra Bio and MetaVia in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.